ArticleLaboratory animal research2026
Ameliorative effect of Gastrodia elata Blume extract on inflammation in a rat model of osteoarthritis.
Article in Laboratory animal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is characterized by progressive articular cartilage degeneration, in which inflammatory mediators drive MMP-mediated matrix breakdown and chondrocyte apoptosis, ultimately leading to pain and functional impairment. Although often described as a "wear-and-tear" disease, increasing evidence highlights immune/inflammatory signaling as a key contributor to OA progression. Gastrodia elata Blume (GEB) has reported anti-inflammatory and immunomodulatory activities, but its preventive potential in OA remains unclear. This study evaluated GEB extract in a widely used monosodium iodoacetate (MIA)-induced OA rat model. Male Sprague-Dawley rats (5 weeks old) were assigned to CON, OA, OA + L-GEB, and OA + H-GEB groups; GEB was administered orally once daily for 5 weeks, and OA was induced by intra-articular MIA (3 mg/50 µL) at day 21.
resultsGEB improved gross cartilage surface appearance and histopathological outcomes (HE, Safranin O, Alcian blue; Mankin and OARSI scores), showing reduced cartilage damage and better preservation of proteoglycan staining compared with the OA group. Consistently, GEB decreased IL-6, MMP-13, and cleaved caspase-3 in cartilage (IHC) and reduced TUNEL-positive cells, indicating suppression of inflammatory signaling and chondrocyte apoptosis. RT-qPCR further showed downregulation of NF-κB, IL-6, MMP-9, MMP-13, and TIMP-1 mRNA levels in GEB-treated groups versus OA.
conclusionsGEB extract attenuated inflammatory and catabolic responses and inhibited chondrocyte apoptosis in MIA-induced OA, supporting its potential as a prophylactic strategy for localized inflammatory pathology such as osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.